$3.62 0.0 0.0%
Last Trade - 05/03/21
| Market Cap | ÂŁ30.2m |
| Enterprise Value | ÂŁ39.2m |
| Revenue | ÂŁn/a |
| Position in Universe | 5603rd / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | July 22, 2003 |
| Public Since | July 7, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | 17 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 11,536,294 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Jerusalem Biopark,2Nd Floor Hadassah Ein Kerem Campus, JERUSALEM, 00000, Israel |
| Web | http://www.biondvax.com |
| Phone | +972 8 9302529 |
| Contact | () |
| Auditors | Kost, Forer, Gabbay & Kasierer |
As of 05/03/21, shares in BiondVax Pharmaceuticals are trading at $3.62, giving the company a market capitalisation of ÂŁ30.2m. This share price information is delayed by 15 minutes.
Shares in BiondVax Pharmaceuticals are currently trading at $3.62 and the price has moved by -55.85% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BiondVax Pharmaceuticals price has moved by -65.18% over the past year.
Of the analysts with advisory recommendations for BiondVax Pharmaceuticals, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for BiondVax Pharmaceuticals is Not available. You can view the full broker recommendation list by unlocking its StockReport.
BiondVax Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:
BiondVax Pharmaceuticals does not currently pay a dividend.
BiondVax Pharmaceuticals does not currently pay a dividend.
BiondVax Pharmaceuticals does not currently pay a dividend.
To buy shares in BiondVax Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BiondVax Pharmaceuticals are currently trading at $3.62, giving the company a market capitalisation of ÂŁ30.2m.
Here are the trading details for BiondVax Pharmaceuticals:
Based on an overall assessment of its quality, value and momentum, BiondVax Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in BiondVax Pharmaceuticals are currently priced at $3.62. At that level they are trading at 89.4% discount to the analyst consensus target price of 0.00.
Analysts covering BiondVax Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.199704 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BiondVax Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -91.54%. At the current price of $3.62, shares in BiondVax Pharmaceuticals are trading at -82.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for BiondVax Pharmaceuticals.
BiondVax Pharmaceuticals's management team is headed by:
Here are the top five shareholders of BiondVax Pharmaceuticals based on the size of their shareholding:
